Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observer-blinded, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac COVID-19 Vaccines or One Formulation of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) Determined in a lead-in Formulation Finding in Healthy Adults.

NCT05087368 is registered in ClinicalTrials.gov with D'Or Institute for Research and Education as lead sponsor.

NCT NCT05087368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05087368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observer-blinded, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac COVID-19 Vaccines or One Formulation of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) Determined in a lead-in Formulation Finding in Healthy Adults.
Lead sponsor
D'Or Institute for Research and Education
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
April 1, 2022
Enrollment
520 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid19